Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2022-02-18
2038-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigation of individual variability in the development of infectious diseases began in the early 20th. The first evidence to support the hypothesis that individual variability variability and immune deficiencies were hereditary came from observations of familial cases or genetic isolates genetic isolates (from a homogeneous population) of rare or common infectious diseases, which in some cases Mendelian heredity hat predisposition to infectious diseases runs in families even more so than diseases associated with less determined environmental factors, such as certain cancers. such as certain cancers. Finally, studies comparing the rate of concordance of infectious diseases between monozygotic and dizygotic twins also implicate genetic factors in disease susceptibility.
These observations were validated by the discovery of genetic defects associated with severe infectious diseases, leading to proof of concept. While a number of hereditary immune deficiencies associated with susceptibility to multiple pathogens or microorganisms, a growing number of new and rare new and rare immune deficiencies conferring restricted susceptibility to infections caused by a single caused by a single pathogen family, or even a single pathogen, in otherwise healthy children, have recently been identified (one gene, one pathogen). As a result, a dozen Mendelian clinical syndromes characterized by restricted susceptibility are now known. Over the last 20 years, it has been proven that these "idiopathic" infections were immune deficiencies.
The investigators now wish to study new severe infections, including but not limited to viral, fungal and bacterial infections. viral, fungal, bacterial and parasitic infections. This should lead to a better understanding of the pathophysiology of each disease, the development of new therapeutics and better patient care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections
NCT00597090
Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection)
NCT04644146
Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
NCT02735824
Genetic Basis of Immunodeficiency
NCT00055172
Genotype and Susceptibility to COVID-19
NCT04799834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The prevalence of the various severe infections we wish to explore ranges from one case in 50,000 to one case in 1,000,000 individuals; consequently, we plan to recruit only a small cohort of patients per pathology. Due to the exploratory nature of this research, no sample size calculation is possible.
ELIGIBILITY CRITERIA
Inclusion criteria :
1. Index cases (patients)
* Informed consent signed by the patient. In the case of a minor patient, consent must be signed by the holders of parental authority. In the case of a protected adult patient, consent is signed by his or her signed by the patient's legal representative. In the case of an adult patient unable to consent at the time of consent is signed by a family member.
* have a proven rare and severe infection defined by at least one of the following elements:
* Acute, life-threatening infection requiring hospitalization, especially in an intensive particularly in intensive care.
* Recurrent and/or chronic infections requiring frequent hospitalization or follow-up visits hospitalization or follow-up visits (dermatology, cardiology, neurology, infectious diseases, immunology, etc.), infectious diseases, immunology, etc.).
* Acute and/or chronic infections leading to sequelae (motor or cognitive deficits, etc.).
* Disseminated infection by an opportunistic microbe.
* be hospitalized or followed in a specialized hospital ward, emergency room or intensive care unit
* be affiliated to a Social Security scheme.
2. Related
* have informed consent signed by the adult relative. In the case of a minor relative, the consent is consent is signed by the holders of parental authority. In the case of an adult relative the consent is signed by his or her legal representative
* be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces
* be affiliated to a Social Security system
Non-inclusion criteria :
1. Index case:4/4 C18-41 \_Predisposition\_Synopsis\_V2.0\_20220324
* Acquired immunodeficiency (having received immunosuppressive treatment in the 3 months prior to the onset of the disease or HIV-positive)
* Pregnant at the time of illness
* Person under court protection
2. Related persons :
* Pregnant or breast-feeding woman
* Person under court protection
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Predisposition
individuals suffering of having previously suffered of severe infectious diseases
Blood samples drawing
10 ml of periferal blood
Skin biopsy
Skin biopsy only in some index cases depending of the pathology at the recruitment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples drawing
10 ml of periferal blood
Skin biopsy
Skin biopsy only in some index cases depending of the pathology at the recruitment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* to have a proven rare and severe infection
* to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care
* to be affiliated to the French Social Security system
* for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces
Exclusion Criteria
* pregnant woman at the time of illness
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'Etudes des Déficits Immunitaires (CEDI), Hôpital Necker-Enfants
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C18-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.